The present invention provides a method of diagnosis of a brain damage-related disorder or the possibility thereof in a subject suspected of suffering therefrom, which comprises detecting one or more polypeptides or variants thereof selected from serum amyloid A, neuromodulin, calcyphosphine, RNA binding regulatory subunit, ubiquitin fusion degradation protein 1 homolog, nucleoside diphosphate kinase A, or cathepsin D in a sample of body fluid taken from the subject.
MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF